Late effects of childhood cancer and its treatment

Pediatric Clinics of North America

Volumn 62, Issue 1, 2015, Pages 275-300

  Landier, Wendy ^a   Armenian, Saro ^a   Bhatia, Smita ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cancer; Childhood; Late effects; Treatment

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLADDER CANCER; BONE DENSITY; BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CATCH UP GROWTH; CHILDHOOD CANCER; COGNITIVE DEFECT; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG EFFECT; FOLLOW UP; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLIOMA; GONAD FUNCTION; HEARING IMPAIRMENT; HEART FUNCTION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG FUNCTION; MELANOMA; MENINGIOMA; MORBIDITY; NONHODGKIN LYMPHOMA; OBESITY; OSTEOPOROSIS; RADIATION DOSE; REVIEW; SALIVARY GLAND TUMOR; SARCOMA; SEX DIFFERENCE; SURVIVAL RATE; THYROID CANCER; THYROID DISEASE; TREATMENT PLANNING; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; RADIOTHERAPY; RISK ASSESSMENT; SURVIVOR;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MORBIDITY; NEOPLASMS; RADIOTHERAPY; RISK ASSESSMENT; SURVIVORS;

EID: 84915751178     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2014.09.017     Document Type: Review

References (184)

1. Robison L.L., Hudson M.M. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer 2014, 14:61-70.
2. Ward E., Desantis C., Robbins A., et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014, 64:83-103.
3. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. NEngl J Med 2006, 355:1572-1582.
4. Hudson M.M., Ness K.K., Gurney J.G., et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013, 309:2371-2381.
5. Armenian S.H., Sun C.L., Kawashima T., et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011, 118:1413-1420.
6. Childhood cancer survivorship: improving care and quality of life 2003, National Academies Press, Washington, DC. M. Hewitt, S.L. Weiner, J.V. Simone (Eds.).
7. Landier W., Bhatia S., Eshelman D.A., et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. JClin Oncol 2004, 22:4979-4990.
8. Children's Oncology Group Long-term follow-up guidelines for survivors ofchildhood, adolescent, and young adult cancers, version 4.0 2013, Children's Oncology Group, Monrovia (CA), Available at:, Accessed September 15, 2014. http://www.survivorshipguidelines.org.
9. UK Children's Cancer Study Group Late Effects Group. Therapy based long term follow up practice statement, UKCCSG. 2011. Available at: Accessed August 5, 2014. http://www.cclg.org.uk/dynamic_files/LTFU-full.pdf.
10. Dutch Childhood Oncology Group. Richtlijn follow-up na kinderkanker meer dan 5 jaar na diagnose. Den Haag/Amsterdam, SKION, 2010. [in Dutch]. Available at: Accessed August 5, 2014. http://www.skion.nl/.
11. Scottish Intercollegiate Guidelines Network: long term follow up of survivors of childhood cancer. A national clinical guideline, SIGN. 2013. Available at: Accessed August 5, 2014. http://www.sign.ac.uk/guidelines/fulltext/132/index.html.
12. Kremer L.C., Mulder R.L., Oeffinger K.C., et al. Aworldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer 2013, 60:543-549.
13. Schell M.J., McHaney V.A., Green A.A., et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. JClin Oncol 1989, 7:754-760.
14. Bates D.E., Beaumont S.J., Baylis B.W. Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother 2002, 36:446-451.
15. Knight K.R., Kraemer D.F., Neuwelt E.A. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. JClin Oncol 2005, 23:8588-8596.
16. Landier W., Knight K., Wong F.L., et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales-a report from the Children's Oncology Group. JClin Oncol 2014, 32:527-534.
17. Brock P.R., Bellman S.C., Yeomans E.C., et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991, 19:295-300.
18. Parsons S.K., Neault M.W., Lehmann L.E., et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998, 22:669-674.
19. Ilveskoski I., Saarinen U.M., Wiklund T., et al. Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Med Pediatr Oncol 1996, 27:26-31.
20. Weatherly R.A., Owens J.J., Catlin F.I., et al. cis-platinum ototoxicity in children. Laryngoscope 1991, 101:917-924.
21. Simon M.V. Neurophysiologic intraoperative monitoring of the vestibulocochlear nerve. JClin Neurophysiol 2011, 28:566-581.
22. Paulino A.C., Simon J.H., Zhen W., et al. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2000, 48:1489-1495.
23. Young Y.H., Lu Y.C. Mechanism of hearing loss in irradiated ears: a long-term longitudinal study. Ann Otol Rhinol Laryngol 2001, 110:904-906.
24. Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 2000, 15:603-630.
25. Mulhern R.K., Fairclough D., Ochs J. Aprospective comparison of neuropsychological performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. JClin Oncol 1991, 9:1348-1356.
26. Butler R.W., Haser J.K. Neurocognitive effects of treatment for childhood cancer. Ment Retard Dev Disabil Res Rev 2006, 12:184-191.
27. Peterson C.C., Johnson C.E., Ramirez L.Y., et al. Ameta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2008, 51:99-104.
28. Clanton N.R., Klosky J.L., Li C., et al. Fatigue, vitality, sleep, and neurocognitive functioning in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 2011, 117:2559-2568.
29. Reimers T.S., Ehrenfels S., Mortensen E.L., et al. Cognitive deficits in long-term survivors of childhood brain tumors: identification of predictive factors. Med Pediatr Oncol 2003, 40:26-34.
30. Walter A.W., Mulhern R.K., Gajjar A., et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. JClin Oncol 1999, 17:3720-3728.
31. Palmer S.L., Gajjar A., Reddick W.E., et al. Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology 2003, 17:548-555.
32. Silber J.H., Radcliffe J., Peckham V., et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. JClin Oncol 1992, 10:1390-1396.
33. Ris M.D., Packer R., Goldwein J., et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. JClin Oncol 2001, 19:3470-3476.
34. Mulhern R.K., Kepner J.L., Thomas P.R., et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. JClin Oncol 1998, 16:1723-1728.
35. Ellenberg L., McComb J.G., Siegel S.E., et al. Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery 1987, 21:638-644.
36. Ellenberg L., Liu Q., Gioia G., et al. Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the Childhood Cancer Survivor Study. Neuropsychology 2009, 23:705-717.
37. Kiehna E.N., Mulhern R.K., Li C., et al. Changes in attentional performance of children and young adults with localized primary brain tumors after conformal radiation therapy. JClin Oncol 2006, 24:5283-5290.
38. Mabbott D.J., Penkman L., Witol A., et al. Core neurocognitive functions in children treated for posterior fossa tumors. Neuropsychology 2008, 22:159-168.
39. Mulhern R.K., Merchant T.E., Gajjar A., et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004, 5:399-408.
40. Nagel B.J., Delis D.C., Palmer S.L., et al. Early patterns of verbal memory impairment in children treated for medulloblastoma. Neuropsychology 2006, 20:105-112.
41. Krull K.R., Brinkman T.M., Li C., et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. JClin Oncol 2013, 31:4407-4415.
42. Krull K.R., Okcu M.F., Potter B., et al. Screening for neurocognitive impairment in pediatric cancer long-term survivors. JClin Oncol 2008, 26:4138-4143.
43. Campbell L.K., Scaduto M., Sharp W., et al. Ameta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer 2007, 49:65-73.
44. Jain N., Brouwers P., Okcu M.F., et al. Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia. Cancer 2009, 115:4238-4245.
45. Kadan-Lottick N.S., Zeltzer L.K., Liu Q., et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. JNatl Cancer Inst 2010, 102:881-893.
46. Kirchhoff A.C., Krull K.R., Ness K.K., et al. Physical, mental, and neurocognitive status and employment outcomes in the childhood cancer survivor study cohort. Cancer Epidemiol Biomarkers Prev 2011, 20:1838-1849.
47. Krull K.R., Annett R.D., Pan Z., et al. Neurocognitive functioning and health-related behaviours in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Eur J Cancer 2011, 47:1380-1388.
48. Kadan-Lottick N.S., Brouwers P., Breiger D., et al. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. JClin Oncol 2009, 27:5986-5992.
49. Conklin H.M., Krull K.R., Reddick W.E., et al. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. JNatl Cancer Inst 2012, 104:1386-1395.
50. Buizer A.I., de Sonneville L.M., Veerman A.J. Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature. Pediatr Blood Cancer 2009, 52:447-454.
51. Spiegler B.J., Kennedy K., Maze R., et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. JClin Oncol 2006, 24:3858-3864.
52. Waber D.P., Turek J., Catania L., et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL consortium protocol 95-01. JClin Oncol 2007, 25:4914-4921.
53. Lipshultz S.E., Adams M.J., Colan S.D., et al. Long-term cardiovascular toxicity inchildren, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013, 128:1927-1995.
54. Mulrooney D.A., Yeazel M.W., Kawashima T., et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009, 339:b4606.
55. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. NEngl J Med 2000, 342:1077-1084.
56. van Dalen E.C., Caron H.N., Dickinson H.O., et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008, (2). CD003917.
57. van Dalen E.C., van der Pal H.J., Caron H.N., et al. Different dosage schedules forreducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2009, (4). CD005008.
58. van Dalen E.C., Michiels E.M., Caron H.N., et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010, (3). CD005006.
59. Lipshultz S.E., Scully R.E., Lipsitz S.R., et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010, 11:950-961.
60. Magnano L.C., Martinez Cibrian N., Andrade Gonzalez X., et al. Cardiac complications of chemotherapy: role of prevention. Curr Treat Options Cardiovasc Med 2014, 16:312.
61. Adams M.J., Lipsitz S.R., Colan S.D., et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. JClin Oncol 2004, 22:3139-3148.
62. Liles A., Blatt J., Morris D., et al. Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care physician. Cleve Clin J Med 2008, 75:531-539.
63. Motosue M.S., Zhu L., Srivastava K., et al. Pulmonary function after whole lung irradiation in pediatric patients with solid malignancies. Cancer 2012, 118:1450-1456.
64. Weiner D.J., Maity A., Carlson C.A., et al. Pulmonary function abnormalities in children treated with whole lung irradiation. Pediatr Blood Cancer 2006, 46:222-227.
65. Mulder R.L., Thonissen N.M., van der Pal H.J., et al. Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax 2011, 66:1065-1071.
66. Collaco J.M., Gower W.A., Mogayzel P.J. Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: overview, diagnostic considerations, and infectious complications. Pediatr Blood Cancer 2007, 49:117-126.
67. Gower W.A., Collaco J.M., Mogayzel P.J. Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: non-infectious and long-term complications. Pediatr Blood Cancer 2007, 49:225-233.
68. Chemaitilly W., Hudson M.M. Update on endocrine and metabolic therapy-related late effects observed in survivors of childhood neoplasia. Curr Opin Endocrinol Diabetes Obes 2014, 21:71-76.
69. Gurney J.G., Kadan-Lottick N.S., Packer R.J., et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors-Childhood Cancer Survivor Study. Cancer 2003, 97:663-673.
70. Chow E.J., Friedman D.L., Stovall M., et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the childhood cancer survivor study. Pediatr Blood Cancer 2009, 53:432-437.
71. Clifton D.K., Bremner W.J. The effect of testicular x-irradiation on spermatogenesis in man. A comparison with the mouse. JAndrol 1983, 4:387-392.
72. Nandagopal R., Laverdiere C., Mulrooney D., et al. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 2008, 69:65-74.
73. Green D.M., Kawashima T., Stovall M., et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JClin Oncol 2010, 28:332-339.
74. Shalet S.M., Beardwell C.G., Jacobs H.S., et al. Testicular function following irradiation of the human prepubertal testis. Clin Endocrinol (Oxf) 1978, 9:483-490.
75. Meistrich M.L. Male gonadal toxicity. Pediatr Blood Cancer 2009, 53:261-266.
76. Rivkees S.A., Crawford J.D. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988, 259:2123-2125.
77. Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol 1999, 33:2-8.
78. Couto-Silva A.C., Trivin C., Thibaud E., et al. Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transplant 2001, 28:67-75.
79. Thomsett M.J., Conte F.A., Kaplan S.L., et al. Endocrine and neurologic outcome in childhood craniopharyngioma: review of effect of treatment in 42 patients. JPediatr 1980, 97:728-735.
80. Jacobsen K.D., Ous S., Waehre H., et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 1999, 80:249-255.
81. Ginsberg J.P., Hobbie W.L., Ogle S.K., et al. Prevalence of and risk factors for hydrocele in survivors of Wilms tumor. Pediatr Blood Cancer 2004, 42:361-363.
82. Green D.M., Sklar C.A., Boice J.D., et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. JClin Oncol 2009, 27:2374-2381.
83. Chemaitilly W., Mertens A.C., Mitby P., et al. Acute ovarian failure in the childhood cancer survivor study. JClin Endocrinol Metab 2006, 91:1723-1728.
84. Chemaitilly W., Sklar C.A. Endocrine complications of hematopoietic stem cell transplantation. Endocrinol Metab Clin North Am 2007, 36:983-998. ix.
85. Sarafoglou K., Boulad F., Gillio A., et al. Gonadal function after bone marrow transplantation for acute leukemia during childhood. JPediatr 1997, 130:210-216.
86. Afify Z., Shaw P.J., Clavano-Harding A., et al. Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. Bone Marrow Transplant 2000, 25:1087-1092.
87. Read M.D., Edey K.A., Hapeshi J., et al. The age of ovarian failure following premenopausal hysterectomy with ovarian conservation. Menopause Int 2010, 16:56-59.
88. Sklar C., Wolden S. Therapy for pediatric brain tumors and the risk of growth hormone deficiency. JClin Oncol 2011, 29:4743-4744.
89. Chow E.J., Friedman D.L., Yasui Y., et al. Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. JPediatr 2007, 150:370-375. 375.e1.
90. Viana M.B., Vilela M.I. Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review. Pediatr Blood Cancer 2008, 50:509-516. [discussion: 517].
91. Gurney J.G., Ness K.K., Stovall M., et al. Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. JClin Endocrinol Metab 2003, 88:4731-4739.
92. Schriock E.A., Schell M.J., Carter M., et al. Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. JClin Oncol 1991, 9:400-405.
93. Laughton S.J., Merchant T.E., Sklar C.A., et al. Endocrine outcomes for children withembryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. JClin Oncol 2008, 26:1112-1118.
94. Kiltie A.E., Lashford L.S., Gattamaneni H.R. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol 1997, 28:348-354.
95. Sanders J.E. Growth and development after hematopoietic cell transplant in children. Bone Marrow Transplant 2008, 41:223-227.
96. Hudson M.M., Neglia J.P., Woods W.G., et al. Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer 2012, 58:334-343.
97. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. JClin Oncol 2003, 21:1359-1365.
98. Garmey E.G., Liu Q., Sklar C.A., et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. JClin Oncol 2008, 26:4639-4645.
99. Green D.M., Cox C.L., Zhu L., et al. Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JClin Oncol 2012, 30:246-255.
100. Rogers P.C., Meacham L.R., Oeffinger K.C., et al. Obesity in pediatric oncology. Pediatr Blood Cancer 2005, 45:881-891.
101. Armstrong G.T., Oeffinger K.C., Chen Y., et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. JClin Oncol 2013, 31:3673-3680.
102. Blijdorp K., van den Heuvel-Eibrink M.M., Pieters R., et al. Obesity is underestimated using body mass index and waist-hip ratio in long-term adult survivors of childhood cancer. PLoS One 2012, 7:e43269.
103. Gurney J.G., Ness K.K., Sibley S.D., et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006, 107:1303-1312.
104. Oeffinger K.C., Adams-Huet B., Victor R.G., et al. Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. JClin Oncol 2009, 27:3698-3704.
105. Kourti M., Tragiannidis A., Makedou A., et al. Metabolic syndrome in children andadolescents with acute lymphoblastic leukemia after the completion of chemotherapy. JPediatr Hematol Oncol 2005, 27:499-501.
106. Florin T.A., Fryer G.E., Miyoshi T., et al. Physical inactivity in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2007, 16:1356-1363.
107. Moller D.E., Flier J.S. Insulin resistance-mechanisms, syndromes, and implications. NEngl J Med 1991, 325:938-948.
108. Lustig R.H. Autonomic dysfunction of the beta-cell and the pathogenesis of obesity. Rev Endocr Metab Disord 2003, 4:23-32.
109. Askari H., Tykodi G., Liu J.M., et al. Fasting plasma leptin level is a surrogate measure of insulin sensitivity. JClin Endocrinol Metab 2010, 95:3836-3843.
110. Link K., Moell C., Garwicz S., et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. JClin Endocrinol Metab 2004, 89:5003-5012.
111. Ness K.K., Oakes J.M., Punyko J.A., et al. Prevalence of the metabolic syndrome in relation to self-reported cancer history. Ann Epidemiol 2005, 15:202-206.
112. Meacham L.R., Sklar C.A., Li S., et al. Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch Intern Med 2009, 169:1381-1388.
113. Wasilewski-Masker K., Kaste S.C., Hudson M.M., et al. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics 2008, 121:e705-e713.
114. Haddy T.B., Mosher R.B., Reaman G.H. Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist 2001, 6:278-285.
115. Kaste S.C., Jones-Wallace D., Rose S.R., et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001, 15:728-734.
116. Krishnamoorthy P., Freeman C., Bernstein M.L., et al. Osteopenia in children who have undergone posterior fossa or craniospinal irradiation for brain tumors. Arch Pediatr Adolesc Med 2004, 158:491-496.
117. Kadan-Lottick N.S., Dinu I., Wasilewski-Masker K., et al. Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study. JClin Oncol 2008, 26:3038-3045.
118. Kawedia J.D., Kaste S.C., Pei D., et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011, 117:2340-2347. [quiz: 2556].
119. Sala A., Mattano L.A., Barr R.D. Osteonecrosis in children and adolescents with cancer-an adverse effect of systemic therapy. Eur J Cancer 2007, 43:683-689.
120. Fan C., Cool J.C., Scherer M.A., et al. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Bone 2009, 44:61-70.
121. Yang L., Boyd K., Kaste S.C., et al. Amouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. JOrthop Res 2009, 27:169-175.
122. Yang L., Panetta J.C., Cai X.J., et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. JClin Oncol 2008, 26:1932-1939.
123. Mattano L.A., Sather H.N., Trigg M.E., et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the children's cancer group. JClin Oncol 2000, 18:3262-3272.
124. te Winkel ML, Appel I.M., Pieters R., et al. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica 2008, 93:1570-1574.
125. Niinimaki R.A., Harila-Saari A.H., Jartti A.E., et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. JClin Oncol 2007, 25:1498-1504.
126. Karimova E.J., Rai S.N., Howard S.C., et al. Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. JClin Oncol 2007, 25:1525-1531.
127. Friedman D.L., Whitton J., Leisenring W., et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. JNatl Cancer Inst 2010, 102:1083-1095.
128. Mertens A.C., Liu Q., Neglia J.P., et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study. JNatl Cancer Inst 2008, 100:1368-1379.
129. Armstrong G.T., Liu W., Leisenring W., et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. JClin Oncol 2011, 29:3056-3064.
130. Bhatia S., Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002, 2:124-132.
131. Bhatia S., Yasui Y., Robison L.L., et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. JClin Oncol 2003, 21:4386-4394.
132. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
133. Thirman M.J., Larson R.A. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996, 10:293-320.
134. Pedersen-Bjergaard J., Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991, 78:1147-1148.
135. Neglia J.P., Friedman D.L., Yasui Y., et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. JNatl Cancer Inst 2001, 93:618-629.
136. Henderson T.O., Amsterdam A., Bhatia S., et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010, 152:444-455. W144-54.
137. Bhatia S., Robison L.L., Oberlin O., et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. NEngl J Med 1996, 334:745-751.
138. Guibout C., Adjadj E., Rubino C., et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. JClin Oncol 2005, 23:197-204.
139. Kenney L.B., Yasui Y., Inskip P.D., et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 2004, 141:590-597.
140. Jenkinson H.C., Hawkins M.M., Stiller C.A., et al. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer 2004, 91:1905-1910.
141. Inskip P.D., Curtis R.E. New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer 2007, 121:2233-2240.
142. Taylor A.J., Winter D.L., Stiller C.A., et al. Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain: a population-based study. Int J Cancer 2007, 120:384-391.
143. Ng A.K., Bernardo M.V., Weller E., et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100:1989-1996.
144. Travis L.B., Hill D.A., Dores G.M., et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290:465-475.
145. Inskip P.D., Robison L.L., Stovall M., et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. JClin Oncol 2009, 27:3901-3907.
146. Sklar C., Whitton J., Mertens A., et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. JClin Endocrinol Metab 2000, 85:3227-3232.
147. Sigurdson A.J., Ronckers C.M., Mertens A.C., et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005, 365:2014-2023.
148. Ronckers C.M., Sigurdson A.J., Stovall M., et al. Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers. Radiat Res 2006, 166:618-628.
149. Bhatti P., Veiga L.H., Ronckers C.M., et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010, 174:741-752.
150. Henderson T.O., Whitton J., Stovall M., et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. JNatl Cancer Inst 2007, 99:300-308.
151. Henderson T.O., Rajaraman P., Stovall M., et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys 2012, 84:224-230.
152. Hawkins M.M., Wilson L.M., Burton H.S., et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. JNatl Cancer Inst 1996, 88:270-278.
153. Le Vu B., de Vathaire F., Shamsaldin A., et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998, 77:370-377.
154. Newton W.A., Meadows A.T., Shimada H., et al. Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer 1991, 67:193-201.
155. Bielack S.S., Rerin J.S., Dickerhoff R., et al. Osteosarcoma after allogeneic bone marrow transplantation. A report of four cases from the Cooperative Osteosarcoma Study Group (COSS). Bone Marrow Transplant 2003, 31:353-359.
156. Garwicz S., Anderson H., Olsen J.H., et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000, 88:672-678.
157. Kony S.J., de Vathaire F., Chompret A., et al. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 1997, 350:91-95.
158. Tabone M.D., Terrier P., Pacquement H., et al. Outcome of radiation-related osteosarcoma after treatment of childhood and adolescent cancer: a study of 23 cases. JClin Oncol 1999, 17:2789-2795.
159. Ferrari C., Bohling T., Benassi M.S., et al. Secondary tumors in bone sarcomas after treatment with chemotherapy. Cancer Detect Prev 1999, 23:368-374.
160. van Leeuwen F.E., Klokman W.J., Stovall M., et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. JNatl Cancer Inst 1995, 87:1530-1537.
161. Neglia J.P., Robison L.L., Stovall M., et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JNatl Cancer Inst 2006, 98:1528-1537.
162. Bhatia S., Sather H.N., Pabustan O.B., et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002, 99:4257-4264.
163. Little M.P., de Vathaire F., Shamsaldin A., et al. Risks of brain tumour following treatment for cancer in childhood: modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer 1998, 78:269-275.
164. Goshen Y., Stark B., Kornreich L., et al. High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007, 49:294-297.
165. Ron E., Modan B., Boice J.D., et al. Tumors of the brain and nervous system after radiotherapy in childhood. NEngl J Med 1988, 319:1033-1039.
166. Bowers D.C., Nathan P.C., Constine L., et al. Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. Lancet Oncol 2013, 14:E321-E328.
167. Taylor A.J., Little M.P., Winter D.L., et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. JClin Oncol 2010, 28:5287-5293.
168. Frobisher C., Gurung P.M., Leiper A., et al. Risk of bladder tumours after childhood cancer: the British Childhood Cancer Survivor Study. BJU Int 2010, 106:1060-1069.
169. Olsen J.H., Garwicz S., Hertz H., et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ 1993, 307:1030-1036.
170. Bassal M., Mertens A.C., Taylor L., et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JClin Oncol 2006, 24:476-483.
171. Metayer C., Lynch C.F., Clarke E.A., et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. JClin Oncol 2000, 18:2435-2443.
172. Travis L.B., Curtis R.E., Glimelius B., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. JNatl Cancer Inst 1995, 87:524-530.
173. Kaldor J.M., Day N.E., Kittelmann B., et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer 1995, 63:1-6.
174. Wilson C.L., Ness K.K., Neglia J.P., et al. Renal carcinoma after childhood cancer: a report from the childhood cancer survivor study. JNatl Cancer Inst 2013, 105:504-508.
175. Fleitz J.M., Wootton-Gorges S.L., Wyatt-Ashmead J., et al. Renal cell carcinoma in long-term survivors of advanced stage neuroblastoma in early childhood. Pediatr Radiol 2003, 33:540-545.
176. Hedgepeth R.C., Zhou M., Ross J. Rapid development of metastatic Xp11 translocation renal cell carcinoma in a girl treated for neuroblastoma. JPediatr Hematol Oncol 2009, 31:602-604.
177. Boukheris H., Stovall M., Gilbert E.S., et al. Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 2013, 85:776-783.
178. Schneider A.B., Lubin J., Ron E., et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998, 149:625-630.
179. Curtis R.E., Rowlings P.A., Deeg H.J., et al. Solid cancers after bone marrow transplantation. NEngl J Med 1997, 336:897-904.
180. Pappo A.S., Armstrong G.T., Liu W., et al. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Pediatr Blood Cancer 2013, 60:461-466.
181. Braam K.I., Overbeek A., Kaspers G.J., et al. Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: a systematic review. Pediatr Blood Cancer 2012, 58:665-674.
182. Eng C., Li F.P., Abramson D.H., et al. Mortality from second tumors among long-term survivors of retinoblastoma. JNatl Cancer Inst 1993, 85:1121-1128.
183. Perkins J.L., Liu Y., Mitby P.A., et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. JClin Oncol 2005, 23:3733-3741.
184. Armstrong G.T., Liu Q., Yasui Y., et al. late mortality among 5-year survivors of childhood cancer: a summary from the childhood cancer survivor study. JClin Oncol 2009, 27:2328-2338.